Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| XBiotech Inc.XBIT · Entity 7044 | Director | October 01, 2025 | November 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
XBiotech Inc.
Report date October 01, 2025 · Filed November 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.64 · Expires 2035-10-01 | Direct | 79,115 |
Reported balance
After 2025-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-10-01 · Grant · Acquired 79,115 · Balance 79,115 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2025 Filed Nov 12, 2025 14:53 UTC | XBiotech Inc. XBIT · Entity 7044 | GrantDirector Stock Option · Derivative | 79,115 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001193125-25-276336 · ownership.xml · derivative · entry 1 Kuendig Thomas Martin · CIK 0002088590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,115 Underlying: Common Stock · 79,115 shares Expires 2035-10-01 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.